NF-κB-IN-15

NF-κB-IN-15

• UNSPSC Description: NF-κB-IN-15 (compound 14r) is a potent NF-κB inhibitor. NF-κB-IN-15 decreases the NO levels and inhibits the release of IL-6, TNF-α, and IL-1β in LPS (HY-D1056) -induced cells. NF-κB-IN-15 inhibits LPS-induced phosphorylation of p65 and degradation of IκBα. NF-κB-IN-15 shows anti-inflammatory activity has the potential for the research of acute lung injury (ALI)[1].
• Target Antigen: NF-κB
• Type: Reference compound
• Related Pathways: NF-κB
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/nf-κb-in-15.html
• Solubility: 10 mM in DMSO
• Smiles: CC1=C(C)C=CC=C1N2CCN(C([C@H](CC3=CC(OC)=C(O)C(OC)=C3)[C@@H](C(N4CCN(C5=CC=CC(C)=C5C)CC4)=O)CC6=CC(OC)=C(O)C(OC)=C6)=O)CC2
• Molecular Weight: 794.97
• References & Citations: [1]Zhang J, et al. Total synthesis and structural modification of the dibenzylbutane lignan LCA as a potent anti-inflammatory agent against LPS-induced acute lung injury. Eur J Med Chem. 2024 Feb 20;268:116272.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported